TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00710385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heroin
Description: Heroin (25 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: .4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Bup Dose
Description: 4 and 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Bup Dose
Description: 8mg and 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Bup/Nal Dose
Description: Buprenorphine/Naloxone 4/1 mg, 8/2 mg
Study: NCT00435760

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LAS34273
Description: 1 puff, 1 dat treatment
Study: NCT03793127

Intervention type: OTHER
Group type: OTHER
Intervention: Maximal oxygen consumption (V02 max)
Description: Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.

Intervention type: OTHER
Group type: OTHER
Intervention: Maximal oxygen consumption (V02 max)
Description: Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.

Intervention type: OTHER
Group type: OTHER
Intervention: Brown adipose tissue (BAT) imaging
Description: Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.

Intervention type: OTHER
Group type: OTHER
Intervention: Brown adipose tissue (BAT) imaging
Description: Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle function testing
Description: This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle function testing
Description: This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
Study: NCT00710385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Bup/Nal Dose
Description: Buprenorphine/Naloxone 8/2 mg, 16/4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PCB)
Description: Placebo control administration
Study: NCT03615014

Intervention type: OTHER
Group type: OTHER
Intervention: Filling questionnaires
Description: Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
Study: NCT01851785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) Intervention
Description: Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?
Study: NCT01152177

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic reminder letters
Description: Electronic reminder letters if adherence is not obtained (up to four)
Study: NCT06065592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: SNP
Description: diagnostics of patients' carriers or not of the risk allele(s)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SNP
Description: diagnostics of patients' carriers or not of the risk allele(s)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SNP
Description: diagnostics of patients' carriers or not of the risk allele(s)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SNP
Description: diagnostics of patients' carriers or not of the risk allele(s)

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: SNP
Description: diagnostics of patients' carriers or not of the risk allele(s)
Study: NCT01468636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Zinc
Description: 200 mg BID of oral zinc gluconate x 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg BID x 8 weeks
Study: NCT00548236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based exercise intervention
Description: Exercise counselling offered via telephone calls
Study: NCT02198690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mammography decision aid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home safety pamphlet
Study: NCT04039867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin with Gemcitabine
Description: Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
Study: NCT01399268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
Study: NCT00209898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast initiation procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast initiation procedure
Study: NCT00651625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001
Description: The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional syringe - BD Ref 309604
Description: the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
Study: NCT01475981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition
Study: NCT04045431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAAG-OA
Description: Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Intra-articular injection of 6ml Synvisc-One in the target knee
Study: NCT03037489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-711
Description: MIV-711 administered orally once daily
Study: NCT03272672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Össür Unloading Knee Brace
Description: During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment.
Study: NCT02576652

Intervention type: OTHER
Group type: OTHER
Intervention: Tetracycline
Description: Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Demeclocycline
Description: Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Hip Replacement
Description: Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
Study: NCT01641523

Intervention type: DEVICE
Intervention: CustomBone Service
Description: customized hydroxyapatite cranial prosthesis

Intervention type: DEVICE
Intervention: CustomBone Service
Description: customized hydroxyapatite cranial prosthesis

Intervention type: DEVICE
Intervention: CustomBone Service
Description: customized hydroxyapatite cranial prosthesis
Study: NCT01371539

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
Study: NCT00446407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Screening plus Antidepressants based on practice guidelines
Study: NCT02497950

Intervention type: DEVICE
Intervention: HeartMate 3
Description: Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
Study: NCT02802592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epogen
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Study: NCT04499911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic dextrose 5% in water solution
Description: The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
Study: NCT04548362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meat arm
Description: Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starchy foods arm
Description: Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
Study: NCT04702113

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cipherome Lighthouse Pilot
Description: Preemptive pharmacogenomic testing
Study: NCT00288314

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging, Functional
Description: Structural and functional MRI

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging, Functional
Description: Structural and functional MRI
Study: NCT02802592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Study: NCT04557657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bio Activa
Description: Cement that release fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin Cement
Description: Resin Cement Convinonal
Study: NCT03205488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
Description: 2 capsules taken once daily
Study: NCT01931020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
Study: NCT03205488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
Description: 2 capsules taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 capsules taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 capsules taken once daily
Study: NCT04890626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]
Description: Main randomization

Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib + dexamethasone
Description: Rescue randomization

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Rescue randomization
Study: NCT04928937

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass, sleeve gastrectomy
Description: bariatric surgery with the goal loosing weight
Study: NCT01613599

Intervention type: DRUG
Intervention: Rituximab
Description: Participants received rituximab at the discretion of their treating physicians.
Study: NCT01931020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
Study: NCT00699361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 160 mg I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 160 mg intravenously (IV)
Study: NCT02377401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
Study: NCT04762524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVH vs CVVHD
Description: Patients are initiated on CRRT in either the CVVH or CVVHD modality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CVVH vs CVVHD
Description: Patients are initiated on CRRT in either the CVVH or CVVHD modality
Study: NCT01375465

Intervention type: DEVICE
Group type: OTHER
Intervention: DIOR drug-eluting PTCA balloon
Description: Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
Study: NCT02974894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus Plantarum)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03327168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
Study: NCT02966912

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg of Magnesium Oxide twice daily for 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open label (none)
Study: NCT03435289

Intervention type: DRUG
Group type: OTHER
Intervention: CPI 613 in Combination With Gemcitabine and Nab-paclitaxel
Description: Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min
Study: NCT02274987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized tumor board recommendation
Description: A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy
Description: Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
Study: NCT03327168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Controlled cold exposure is performed before and during PET/CT scan.
Study: NCT02540811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dCELL® ACL Scaffold
Study: NCT06287554

Intervention type: OTHER
Intervention: PRONE POSITION
Description: early placed in prone positions within 24 hours of intubation
Study: NCT01207089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: AZD8329 Oral Solution 20mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo AZD8329 Oral Solution
Study: NCT02126072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Volunteers consume the same volume of water as the would in wine according toe the protocol.
Study: NCT01781351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping the ankle
Study: NCT02831790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fontan Education Videos
Description: The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage
Study: NCT02335060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036mg/Kg) given intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036mg/Kg) given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: A pill given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: A pill given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill given orally with no N-acetylcysteine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill given orally with no N-acetylcysteine.
Study: NCT04133194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 1600 mg Asacol \[mesalazine\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 800 mg Asacol \[mesalazine\]
Study: NCT00228865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile IV insulin therapy
Description: Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Effects of Pulsatile IV Insulin on Cognitive functions
Description: Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
Study: NCT00994994

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: 50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
Study: NCT00261703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Description: Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Description: Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cisplatin + radiotherapy
Description: Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
Study: NCT00199888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124-Iodine-cG250 (124I-cG250)
Study: NCT01120925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC
Description: 2-3 X 109 cells in 20ML suspension IPV in 4 min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133
Description: 5-15 X 106 cells in 20ML suspension IPV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Injection of 20 ml Normal saline via IPV